Smart-Money SignalNeutral · 45/100— Insiders are net sellers over 90 days (-$632K, 7 sales vs 12 buys)
Revenue$136.0M
Net Income-$185.0M
EPS$-1.84
Market Cap$3.3B
Price Performance
Historical data including institutional events
Company Profile
E
Emil Kakkis
CEO & Executive Director
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
